Indaptus Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Indaptus Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$19.83M	-$15.37M	-$16.38M	-$7.73M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$20.85M	-$15.02M	-$15.40M	-$7.71M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-21.00	$-1.00	$-1.00	$-1.89
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-21.00	$-1.00	$-1.00	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$8.51M	$5.79M	$13.36M	$39.13M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$9.31M	$7.34M	$14.92M	$40.58M
Everything the company owes — debt, unpaid bills, and other obligations.	–	$3.39M	$2.85M	$4.68M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$3.15M	$3.94M	$12.08M	$35.90M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$14.80M	-$12.30M	-$13.40M	-$11.29M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	$3854
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	-$11.29M